[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100560665":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":24,"locations":30,"responsibleParty":63,"collaborators":65,"id":70,"slug":71,"hasResults":72,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":10,"eligibilityCriteria":76,"healthyVolunteers":72,"sex":77,"minAge":78,"maxAge":10,"enrollmentInfo":79,"targetDuration":10,"studyType":82,"phases":10,"briefSummary":83,"conditions":84,"keywords":10,"overallStatus":33,"whyStopped":10,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"Wake Forest University Health Sciences","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"AML participants who are receiving or are planned to receive azacitidine plus venetoclax",null,"Buccal swabs for SNPs and pharmacogenomic analysis can occur at any point before or after starting treatment during the study period. Venetoclax peak and trough levels will be obtained during SOC Aza\u002FVen treatments. CYP3A activity will also be evaluated. Demographic and cancer related history will be acquired for each participant. During study participation, cancer treatment details including administration, dose modifications, delays, and reductions, including specific grade 3 toxicities, stem cell transplant status, symptom burden, disease response, and survival will be collected. Participants will be taken off study after three years.",[13],"Other: Biospecimen samples",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"Biospecimen samples","Buccal swabs and Blood samples will be collected throughout study.",[9],[20],{"name":21,"affiliation":22,"role":23},"Brittany Ragon, MD","Atrium Health Wake Forest Baptist Comprehensive Cancer Center","PRINCIPAL_INVESTIGATOR",[25],{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},"Courtney Schepel","CONTACT","(980) 292-0817","courtney.schepel@advocatehealth.org",[31,48],{"facility":32,"status":33,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Levine Cancer Institute","RECRUITING","Charlotte","North Carolina","28204","United States","US",{"type":40,"coordinates":41},"Point",[42,43],-80.84313,35.22709,{"lat":43,"lon":42},[46,47],{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},{"name":21,"role":23,"phone":10,"phoneExt":10,"email":10},{"facility":49,"status":33,"city":50,"state":35,"zip":51,"country":37,"countryCode":38,"cosmosGeoPoint":52,"geoPoint":56,"contacts":57},"Wake Forest Baptist Comprehensive Cancer Center","Winston-Salem","27157",{"type":40,"coordinates":53},[54,55],-80.24422,36.09986,{"lat":55,"lon":54},[58,62],{"name":59,"role":27,"phone":60,"phoneExt":10,"email":61},"Timothy Pardee, MD","336-716-2466","tspardee@wakehealth.edu",{"name":59,"role":23,"phone":10,"phoneExt":10,"email":10},{"type":64,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[66,68],{"name":67,"class":6},"Atrium Health Levine Cancer Institute",{"name":69,"class":6},"Swim Across America","100560665","toxicity-genetic-determinants-and-response-to-azacitidine-and-venetoclax-in-aml-100560665",false,"NCT06580106","Toxicity Genetic Determinants and Response to Azacitidine and Venetoclax in AML","A Prospective Pilot Study of the Genetic Determinants of Toxicity and Response to Azacitidine and Venetoclax in Patients With Newly Diagnosed Acute Myeloid Leukemia Through Evaluation of Polymorphisms in Pharmacokinetic Genes and Venetoclax Levels","Inclusion Criteria:\n\n* Written informed consent and HIPAA authorization for release of personal health information.\n* Age ≥ 18 years of age at the time of enrollment\n* Confirmed diagnosis of AML\n* Planned initial treatment with azacitidine and venetoclax\n* Ability to read and understand the English and\u002For Spanish language\n* As determined by the enrolling investigator, ability of the participant to understand and comply with study procedures for the entire length of the study\n\nExclusion Criteria:\n\n* None","ALL","18 Years",{"count":80,"type":81},50,"ESTIMATED","OBSERVATIONAL","The purpose of this research is to see how certain genetic variations relate to side effects and outcomes experienced while receiving treatment with azacitidine and venetoclax.",[85],"Leukemia, Myeloid, Acute","2026-01-30",{"date":88,"type":89},"2026-02-02","ACTUAL",{"date":91,"type":89},"2025-04-09",{"date":93,"type":81},"2030-01",{"name":5,"class":6},2]